Comprehensive treatment strategy for hepatocellular carcinoma based on surgical treatment in the era of targeted therapy and immunotherapy
10.3760/cma.j.cn115610-20221130-00719
- VernacularTitle:靶向联合免疫治疗时代以外科为主的肝细胞癌综合治疗策略
- Author:
Jianqiang CAI
1
;
Bolun ZHANG
;
Xinyu BI
Author Information
1. 国家癌症中心国家肿瘤临床医学研究中心 中国医学科学院 北京协和医学院肿瘤医院肝胆外科，北京 100021
- Keywords:
Liver neoplasms;
Targeted therapy;
Immunotherapy;
Surgical treatment;
Comprehensive treatment
- From:Chinese Journal of Digestive Surgery
2023;22(2):181-186
- CountryChina
- Language:Chinese
-
Abstract:
Hepatocellular carcinoma is still a severe threat to people′s health of China. Most patients have advanced disease at the time of first diagnosis and lose the opportunity of radical surgery. In the past, the traditional medical drug treatment and radiotherapy are ineffective, which make the treatment of hepatocellular carcinoma into a bottleneck. With the emergence of target therapy represented as tyrosine kinase inhibitors and immunotherapy represented by programmed death-1 antibody and programmed death-ligand 1 antibody, the treatment of hepatocellular carcinoma has entered a new era and patients with advanced hepatocellular carcinoma have seen a new hope. The systemic therapy represented by target therapy and immunotherapy has not only greatly improved the survival of patients with advanced hepatocellular carcinoma, but also changed the treatment concept of hepatocellular carcinoma from single-drug therapy to combined therapy with multiple means. The treatment of hepatocellular carcinoma has changed from the era of surgery as the king to the era of surgery as the mainstay of whole-process management and comprehensive treatment. The authors review previous studies and their own experience to elaborate on the comprehensive treat-ment strategy for hepatocellular carcinoma based on surgical treatment in the era of targeted therapy and immunotherapy.
